---

1. At a Glance – The Chemical Lab That Prints Money… or Just Looks Like It?

Meet Kronox Lab Sciences Ltd — a company that sounds like it belongs in a Breaking Bad sequel but actually sells high-purity chemicals to pharma giants. Now here’s the spicy part:

A ₹500 Cr market cap company quietly generating ₹25 Cr quarterly revenue and ₹6.5 Cr profit, with ROCE of 43.8% and ROE of 32.6%. That’s not normal. That’s suspiciously efficient.

Margins? A juicy 32% operating margin. Debt? Practically zero. Customers? Sun Pharma, Zydus, Sanofi — basically the Avengers of pharma.

But wait…

Growth? Slower than Mumbai traffic during monsoon.
Sales growth (TTM)? ~5%.
Profit growth (TTM)? ~3%.

So what do we have here?

A high-margin, elite chemical supplier… growing like it’s already retired.

And then there’s the cherry on top:

• IPO in 2024 (Offer for Sale — promoters cashed out, not the company raising funds)
• SEBI non-compliance notice in July 2024
• Customer concentration: Top 10 = 51%

So let’s get this straight:

High profitability + low growth + promoter exit + regulatory notice.

Are we looking at a hidden gem… or a well-decorated trap?

Let’s investigate.

---

2. Introduction – The “Too Good to Be Boring” Company

Kronox is not flashy.

No EV story.
No AI buzzword.
No “next big disruption”.

Just chemicals.

And not even exciting chemicals — fine, high-purity chemicals used in pharma, labs, and nutraceuticals.

Basically, Kronox is the guy in class who always scores 90% but never talks.

Now here’s where it gets interesting.

The company:

• Has 185 products
• Serves multiple industries (pharma, biotech, agrochemicals)
• Exports to 20 countries
• Maintains consistent margins >30%

Yet the stock is down:

• ~13% in 6 months
• ~4% in 1 year

Why?

Because markets don’t reward boring consistency. They reward stories.

And Kronox doesn’t have a story… yet.

But here’s the question:

Would you rather own a company that promises 100% growth… or one that quietly delivers 30% margins every year?

---

3. Business Model – WTF Do They Even Do?

Let’s simplify Kronox.

They make ultra-clean chemicals.

Not your local acid or detergent — we’re talking:

• Pharmaceutical excipients
• Lab reagents
• Food-grade chemicals
• Nutraceutical ingredients

Basically, if a pharma company needs ingredients that must be 99.99% pure, Kronox is in the shortlist.

Their products go into:

• Drug manufacturing
• Research labs
• Nutraceuticals
• Cosmetics
• Agrochemicals

So Kronox doesn’t sell directly to consumers.

They sell to companies that sell to consumers.

That means:

• Stable demand
• Sticky clients
• High switching costs

But also:

• Dependency on large clients
• Limited pricing power in some segments

And here’s the kicker:

Top 10 customers = 51% revenue

So if even 2–3 clients walk away, the business will feel it.

Now ask yourself:

Is this a diversified chemical business… or just a few big clients wearing different masks?

---

4. Financials Overview – Numbers Don’t Lie, But They Do Whisper

Quarterly Results = QUARTERLY (Locked)

Financial Comparison Table (₹ Crores)

Metric	Dec 2025 (Latest)	Dec 2024 (YoY)	Sep 2025 (QoQ)	YoY %	QoQ %
Revenue	25.27	24.01	25.53	+5.25%	-1.02%
EBITDA	8.03	8.36	8.65	-3.9%	-7.2%
PAT	6.59	6.53	6.68	+0.9%	-1.3%
EPS (₹)	1.78	1.76	1.80	—	—

Annualised EPS = 1.78 × 4 = ₹7.12

Commentary

• Revenue growth: Meh
• Profit growth: Even more meh
• Margins: Still elite

This is like a cricket player scoring consistent 50s but never hitting centuries.

Reliable… but not exciting.

---

5. Valuation Discussion – Fair Value Range

1. P/E Method

• EPS (Annualised) = ₹7.12